|Mr. Matthew R. Patterson||Co-Founder, Chairman & CEO||780.48k||N/A||1972|
|Ms. Natalie C. Holles||Pres & COO||612.01k||N/A||1973|
|Mr. Thomas P. Soloway||Exec. VP & CFO||525.31k||N/A||1967|
|Mr. Andrew H. Chang||Director of Investor Relations||N/A||N/A||N/A|
|Mr. Mark A. Meltz||Sr. VP & Gen. Counsel||N/A||N/A||1974|
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Audentes Therapeutics, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 8.